{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T16:03:45Z","timestamp":1791389025416,"version":"4.3.3"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Psychiatry"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ajp.2024.104242","type":"journal-article","created":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T22:03:28Z","timestamp":1726610608000},"page":"104242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Exploring the regulatory framework of psychedelics in the US & Europe"],"prefix":"10.1016","volume":"102","author":[{"given":"Hitesh Kumar","family":"Behera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramesh","family":"Joga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sravani","family":"Yerram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveena","family":"Karnati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejaswini","family":"Mergu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kajal","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sowndharya","family":"M","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Nathiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravindra Pal","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1331-4028","authenticated-orcid":false,"given":"Sandeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajp.2024.104242_bib1","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1089\/psymed.2023.0013","article-title":"Psychedelic commercialization: a wide-spanning overview of the emerging psychedelic industry","volume":"1","author":"Aday","year":"2023","journal-title":"Psychedelic Med."},{"key":"10.1016\/j.ajp.2024.104242_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2022.109214","article-title":"Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines","volume":"219","author":"Belouin","year":"2022","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ajp.2024.104242_bib3","unstructured":"Booker, C., MARCH 08, 2023. Booker, Paul, Mace, Dean Introduce Bipartisan Legislation to Promote Research and Access to Potential Life Saving Drugs."},{"key":"10.1016\/j.ajp.2024.104242_bib4","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/S0140-6736(23)00264-7","article-title":"The therapeutic potential of psychedelics: the European regulatory perspective","volume":"401","author":"Butlen-Ducuing","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.ajp.2024.104242_bib5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41386-022-01389-z","article-title":"Towards an understanding of psychedelic-induced neuroplasticity","volume":"48","author":"Calder","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ajp.2024.104242_bib6","unstructured":"Callahan, J., 2020. Legal Status of Psychedelic Drugs and Research Involving Possible Medical Uses."},{"key":"10.1016\/j.ajp.2024.104242_bib7","unstructured":"Canada, H., 2022-10-26. Authorized cannabis retailers in the provinces and territories."},{"key":"10.1016\/j.ajp.2024.104242_bib8","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.ajp.2024.104242_bib9","unstructured":"DEA.Gov, Drug Scheduling."},{"key":"10.1016\/j.ajp.2024.104242_bib10","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.25235","article-title":"Psychoactive drugs in the management of post traumatic stress disorder: a promising new horizon","author":"Elsouri","year":"2022","journal-title":"Cureus 14"},{"key":"10.1016\/j.ajp.2024.104242_bib11","unstructured":"EMCDD, Classification of controlled drugs."},{"key":"10.1016\/j.ajp.2024.104242_bib12","unstructured":"EMA, April 5, 2024. Psychedelic Drugs in Psychiatry A European Regulatory Perspective."},{"key":"10.1016\/j.ajp.2024.104242_bib13","unstructured":"EMA, September 4, 2023. Guideline on clinical investigation of medicinal products in 4 the treatment of depression."},{"key":"10.1016\/j.ajp.2024.104242_bib14","unstructured":"Government, U., 2022. National Survey on Drug Use and Health (NSDUH)."},{"key":"10.1016\/j.ajp.2024.104242_bib15","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ajp.2024.104242_bib16","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw6435","article-title":"Distinct neural mechanisms for the prosocial and rewarding properties of MDMA","volume":"11","author":"Heifets","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ajp.2024.104242_bib17","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pharmthera.2018.11.010","article-title":"Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function","volume":"197","author":"Johnson","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ajp.2024.104242_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.cub.2021.12.009","article-title":"Psychedelics","volume":"32","author":"Kelmendi","year":"2022","journal-title":"Curr. Biol."},{"key":"10.1016\/j.ajp.2024.104242_bib19","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ijnp\/pyaa018","article-title":"Reviewing the potential of psychedelics for the treatment of PTSD","volume":"23","author":"Krediet","year":"2020","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.ajp.2024.104242_bib20","unstructured":"Lam, C., Patel, P., 2022. Food, drug, and cosmetic act."},{"key":"10.1016\/j.ajp.2024.104242_bib21","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/s41591-021-01530-3","article-title":"Psychedelic therapy: a roadmap for wider acceptance and utilization","volume":"27","author":"Marks","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ajp.2024.104242_bib22","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1038\/s41591-023-02565-4","article-title":"MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial","volume":"29","author":"Mitchell","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ajp.2024.104242_bib23","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s00213-019-05249-5","article-title":"MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials","volume":"236","author":"Mithoefer","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ajp.2024.104242_bib24","unstructured":"Newswire, P., March 25, 2022. Global Psychedelic Drugs Markets, 2022-2025: Emergence of Psychedelic-assisted Psychotherapy (PAP) \/ Rising Approval for Additional Psychedelic Drugs \/ Growing Popularity of Psilocybin."},{"key":"10.1016\/j.ajp.2024.104242_bib25","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ajp.2024.104242_bib26","doi-asserted-by":"crossref","unstructured":"Nutt, D., 2019. Psychedelic drugs\u2014a new era in psychiatry? Dialogues in clinical neuroscience.","DOI":"10.31887\/DCNS.2019.21.2\/dnutt"},{"key":"10.1016\/j.ajp.2024.104242_bib27","doi-asserted-by":"crossref","unstructured":"Ona, G., Bouso, J.C., 2019. Can psychedelics be the treatment for the crisis in psychopharmacology?","DOI":"10.20944\/preprints201901.0249.v1"},{"key":"10.1016\/j.ajp.2024.104242_bib28","unstructured":"Parliment, E., March 23, 2023. On substances with psychedelic properties."},{"key":"10.1016\/j.ajp.2024.104242_bib29","first-page":"2023","article-title":"sychedelic Drugs Market by Drug Type (Ketamine, Psilocybin, Others), by Application (Mental Health, Abuse Disorder, Others), by End User (Hospitals, Mental Health Center, Others): global opportunity analysis and industry","author":"Research","year":"2023","journal-title":"Forecast"},{"key":"10.1016\/j.ajp.2024.104242_bib30","unstructured":"Therapeutics, L., February 9, 2024. Lykos Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for MDMA-Assisted Therapy for PTSD."},{"key":"10.1016\/j.ajp.2024.104242_bib31","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/j.jconrel.2022.06.034","article-title":"Sustained drug delivery strategies for treatment of common substance use disorders: promises and challenges","volume":"348","author":"Tijani","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ajp.2024.104242_bib32","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1503\/cmaj.141124","article-title":"Psychedelic medicine: a re-emerging therapeutic paradigm","volume":"187","author":"Tupper","year":"2015","journal-title":"Cmaj"},{"key":"10.1016\/j.ajp.2024.104242_bib33","unstructured":"USFDA, 2019. FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor\u2019s office or clinic."},{"key":"10.1016\/j.ajp.2024.104242_bib34","unstructured":"USFDA, 2021. Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs Frequently Asked Questions Statement of Investigator (Form FDA 1572) (Revision 1)."},{"key":"10.1016\/j.ajp.2024.104242_bib35","unstructured":"USFDA, 2023a. Psychedelic Drugs: Considerations for Clinical Investigations Guidance for Industry."},{"key":"10.1016\/j.ajp.2024.104242_bib36","unstructured":"USFDA, 2023b. Risk Evaluation and Mitigation Strategies | REMS."},{"key":"10.1016\/j.ajp.2024.104242_bib37","unstructured":"white, T., 2021. Psychedelic-Based Therapy Blends Traditional and Alternative Treatments for Depression."}],"container-title":["Asian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201824003356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201824003356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T12:37:46Z","timestamp":1733143066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876201824003356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":37,"alternative-id":["S1876201824003356"],"URL":"https:\/\/doi.org\/10.1016\/j.ajp.2024.104242","relation":{},"ISSN":["1876-2018"],"issn-type":[{"value":"1876-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the regulatory framework of psychedelics in the US & Europe","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajp.2024.104242","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104242"}}